Access Bio엑세스바이오
950130 · KOSDAQ · ₩950130 · 엑세스바이오
₩1,920▼ ₩40 (2.04%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩22M | ₩82M | ₩267M | ₩800M | ₩441M |
| Cost of sales | ₩39M | ₩43M | ₩137M | ₩166M | ₩95M |
| Gross profit | −₩17M | ₩39M | ₩130M | ₩635M | ₩346M |
| Operating income | −₩45M | −₩3.1M | ₩17M | ₩363M | ₩227M |
| Net income | −₩58M | −₩791,702 | −₩4.1M | ₩271M | ₩166M |
| Net income to shareholders | −₩58M | −₩254,825 | −₩2.4M | ₩268M | ₩166M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩424M | ₩504M | ₩536M | ₩699M | ₩373M |
| Current assets | ₩302M | ₩340M | ₩325M | ₩565M | ₩277M |
| Cash and equivalents | ₩225M | ₩233M | ₩215M | ₩373M | ₩168M |
| Total liabilities | ₩34M | ₩60M | ₩81M | ₩205M | ₩128M |
| Current liabilities | ₩17M | ₩27M | ₩34M | ₩155M | ₩117M |
| Borrowings | ₩10M | ₩10M | ₩18M | ₩19M | ₩47M |
| Total equity | ₩389M | ₩444M | ₩455M | ₩494M | ₩245M |
| Shareholders' equity | ₩388M | ₩442M | ₩453M | ₩488M | ₩242M |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩20M | ₩14M | −₩81M | ₩291M | ₩138M |
| Free cash flow | −₩20M | ₩14M | −₩81M | ₩291M | ₩138M |
| Dividends paid | ₩0 | ₩0 | ₩23M | — | — |
Consolidated where available. Amounts in won.
Also known as: Access Bio / 엑세스바이오 / 950130 / KRX:950130
Source: KRX statistical information